Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00258882 · ClinicalTrials.gov registry record
Descriptive, Post-marketing, Passive Surveillance Safety Study of ADACEL™ Vaccine
A clinical trial of Pertussis, sponsored by Sanofi Pasteur, a Sanofi Company.
- Completed
- Registry status
- 327,293
- Enrollment target
- 3
- Study locations
NCT00258882: Completed study of Pertussis, sponsored by Sanofi Pasteur, a Sanofi Company.
NCT00258882 is a study of Pertussis that has completed, run by Sanofi Pasteur, a Sanofi Company. The registered enrollment target is 327,293 participants, above the 15,552-participant average among 14 other Pertussis trials with a reported enrollment target (2005% higher). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00258882, a study of Pertussis, has completed, sponsored by Sanofi Pasteur, a Sanofi Company.
- COMPLETED
- Registry status
- 327,293 participants
- Enrollment target
- 3
- Study locations
Study Summary
To further characterize the vaccine safety profile and to identify any signals of potentially vaccine-related adverse events (AEs) not detected during pre-licensure studies.
Primary Outcome
The twenty one pre-specified outcomes of special interest screened for in this study included: Arthritis, Arthralgia, or Arthropathy; Bell's Palsy; Diabetes; Encephalitis; Encephalopathy; Febrile Illness; Guillain-Barré; Hemolytic Anemia; Hypersensitivity; Idiopathic Thrombocytopenic Purpura (ITP); Lupus; Mixed Connective Tissue Disease; Multiple Sclerosis; Neuralgia; Neuritis; Neuropathy; Rheumatoid Arthritis; Scleroderma; Seizure; Severe Local Reaction; Transverse Myelitis. Comparison of even
Conditions Studied
Interventions
- BIOLOGICAL Tetanus Toxoid, acellular pertussis, diphtheria toxoid
Study Locations (3)
California
- - Oakland
Colorado
- - Aurora
Oregon
- - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 327,293 participants |
| Start Date | 2006-01 |
| Est. Completion | 2012-12 |
What the finished NCT00258882 record still lists
NCT00258882 is an observational study that tracks outcomes without assigning an intervention. Its 327,293 participants enrollment target places it among the larger protocols in the corpus, above the 15,552-participant average among 14 other Pertussis trials with a reported enrollment target (2005% higher).
The record links to 1 condition, with Pertussis appearing as the primary indexed condition, and to 1 intervention - of which Tetanus Toxoid, acellular pertussis, diphtheria toxoid is the first listed.
NCT00258882 reports a single indexed study location in California, Colorado, Oregon.
Frequently Asked Questions
What is clinical trial NCT00258882 about?
NCT00258882 is a clinical study titled "Descriptive, Post-marketing, Passive Surveillance Safety Study of ADACEL™ Vaccine". To further characterize the vaccine safety profile and to identify any signals of potentially vaccine-related adverse events (AEs) not detected during pre-licensure studies.
What is the current status of trial NCT00258882?
This trial is currently completed. The enrollment target is 327,293 participants. The study started on 2006-01. Estimated completion is 2012-12.
What conditions does trial NCT00258882 study?
This clinical trial studies the following conditions: Pertussis.
What interventions are being tested in trial NCT00258882?
The interventions under investigation include: Tetanus Toxoid, acellular pertussis, diphtheria toxoid (BIOLOGICAL).
Who is sponsoring clinical trial NCT00258882?
This trial is sponsored by Sanofi Pasteur, a Sanofi Company, which has 153 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00258882 being conducted?
This trial has 3 study locations across California, Colorado, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pertussis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00258882's enrollment target sits among peer trials
327,293 1st of 14 higher than 14 of 14 other Pertussis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pertussis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pentavalent DTaP-Hep B-IPV
COMPLETED · Phase 2
-
Post-licensure, Modified Double-blind, Multi-center Study Evaluating Safety and Immunogenicity of ADACEL® and BOOSTRIX®
COMPLETED · Phase 4
-
Immunogenicity of Adacel® and BOOSTRIX® Vaccines in Adolescents
COMPLETED · Phase 4
-
Study of DAPTACEL® Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With PENTACEL™
COMPLETED · Phase 4
-
Study on the Safety and Immunogenicity of Boostrix Vaccine in Pregnant Malian Women and Their Infants
COMPLETED · Phase 2
-
Descriptive, Open-label, Multicenter Study of the Safety of Redosing With ADACEL® Vaccine
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05668637 · 318,542 participants
Evaluation and Further Development of an Artificial Intelligence-based Algorithm for Clinical Decision Support
- NCT05365048 · 301,201 participants · NA
Provider Recommendation and HPV Vaccination
- NCT02280733 · 300,000 participants
A Real-World Registry of Chronic Wounds and Ulcers
- NCT06694181 · 300,000 participants
Safe and Explainable AI
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia